Data at SITC Annual Meeting to Highlight Progress of Incyte’s Immuno-oncology Portfolio

Results of a proof-of-concept study of epacadostat, Incyte’s IDO1 inhibitor, in combination with pembrolizumab to be presented as a late-breaking abstract

WILMINGTON, Del.-- Incyte Corporation (Nasdaq:INCY) announces that new data from its investigational immuno-oncology portfolio will be presented at the upcoming Society for Immunotherapy of Cancer (SITC) 30th Anniversary Annual Meeting & Associated Programs, November 4–8, 2015 at the Gaylord National Resort & Convention Center in National Harbor, MD. Safety and efficacy data from a Phase 1/2 study evaluating epacadostat, Incyte’s selective IDO1 inhibitor, in combination with pembrolizumab, an anti-PD-1 therapy, will be presented as a late-breaking oral presentation. Additionally, data from INCB50465, Incyte’s selective PI3Kδ inhibitor, will be presented as a poster.

“We are very pleased that data for both epacadostat and INCB50465 have been selected for presentation at the SITC Annual Meeting next month,” stated Hervé Hoppenot, President and Chief Executive Officer of Incyte. “We look forward to sharing the progress of our immuno-oncology portfolio, which reflects our commitment to developing new medicines that may improve the lives of patients with cancer.”

Incyte abstracts to be presented at SITC include:

Preliminary results from a phase 1/2 study of epacadostat (INCB024360) in combination with pembrolizumab in patients with selected advanced cancers (Abstract #142)

• Friday, November 6, 2015, 12:00-12:15 PM EST
• Maryland Ballroom

Pharmacological inactivation of PI3Kδ in the tumor microenvironment enhances efficacy of other immunotherapeutic agents (Poster #394)

• Friday, November 6, 2015, 6:15–7:30 PM ET and Saturday, November 7, 2015,
  12:45–2:00 PM EST
• Prince George’s Exhibition Hall A

Full session details and data presentation listings for SITC 2015 can be found at: http://www.sitcancer.org/2015.

About Epacadostat

Indoleamine 2,3-dioxygenase 1 (IDO1) is an immunosuppressive enzyme that has been shown to induce regulatory T cell generation and activation, and allow tumors to escape immune surveillance. Epacadostat is an orally bioavailable small molecule inhibitor of IDO1 that has nanomolar potency in both biochemical and cellular assays and has demonstrated potent activity in enhancing T lymphocyte, dendritic cell and natural killer cell responses in vitro, with a high degree of selectivity. Epacadostat has shown proof-of-concept clinical data in patients with unresectable or metastatic melanoma in combination with the CTLA-4 inhibitor ipilimumab, and is currently in four proof-of-concept clinical trials with PD-1 and PD-L1 immune checkpoint inhibitors in a variety of cancer histologies.

About Pembrolizumab

Pembrolizumab, marketed in the U.S. by Merck under the brand name KEYTRUDA^® is a humanized monoclonal antibody that blocks the interaction between PD-1 and its ligands, PD-L1 and PD-L2.

About Incyte

Incyte Corporation is a Wilmington, Delaware-based biopharmaceutical company focused on the discovery, development and commercialization of proprietary therapeutics, primarily for oncology. For additional information on Incyte, please visit the Company’s website at www.incyte.com.

Forward-Looking Statements

Except for the historical information set forth herein, the matters set forth in this press release, including statements regarding the presentation of data regarding the Company’s investigational immuno-oncology portfolio and the effectiveness of such portfolio, contain predictions, estimates and other forward-looking statements. These forward-looking statements are based on the Company’s current expectations and subject to risks and uncertainties that may cause actual results to differ materially, including unanticipated developments and the risks related to the efficacy or safety of the Company’s development pipeline, the results of further research and development, the high degree of risk and uncertainty associated with drug development, clinical trials and regulatory approval processes, other market or economic factors and competitive and technological advances; and other risks detailed from time to time in the Company’s reports filed with the Securities and Exchange Commission, including its Form 10-Q for the quarter ended June 30, 2015. Incyte disclaims any intent or obligation to update these forward-looking statements.

View source version on businesswire.com: http://www.businesswire.com/news/home/20151002005146/en/

Incyte Corporation
Media
Catalina Loveman, +1 302-498-6171
This email address is being protected from spambots. You need JavaScript enabled to view it.
or
Investors
Michael Booth, DPhil
+1 302-498-5914
This email address is being protected from spambots. You need JavaScript enabled to view it.